Gene: SHANK2

22941
AUTS17|CORTBP1|CTTNBP1|ProSAP1|SHANK|SPANK-3
SH3 and multiple ankyrin repeat domains 2
protein-coding
11q13.3-q13.4
Ensembl:ENSG00000162105 MIM:603290 Vega:OTTHUMG00000154615 UniprotKB:Q9UPX8
NG_042866.1
PubMed|SNP Mapped
4   ANCO-SNPs
ND|AD
2   
NA (AD)  NA (ND)   (Frontal_Cortex)
1.467e-1 (AD)  7.499e-1 (ND)

ANCO-SNPs

SNP ID Position Alleles Trait Variation Type
rs3924047chr11:71118812 (GRCh38.p7)T>Calcohol dependenceSNV(Single Nucleotide Variation)
rs11238042chr11:70942895 (GRCh38.p7)G>Aalcohol dependenceSNV(Single Nucleotide Variation)
rs7940843chr11:70680240 (GRCh38.p7)T>Calcohol dependenceSNV(Single Nucleotide Variation)
rs11604385chr11:70574867 (GRCh38.p7)C>Talcohol dependenceSNV(Single Nucleotide Variation)

DNA Methylation

Probe Locus(GRCh37) Gene Region p-val Trait PubMed ID
cg25193885chr11:70328867SHANK2Gene body2.440e-4Alcohol use disorders26763658
cg16163543chr11:70449219SHANK23.100e-12Smoking27651444

Gene Expression in Different Tissues

Temporal and Spatial Expressions (BrainSpan)

Footnote:
SC: sub-cortical regions; SM: sensory-motor regions; FC: frontal cortex; and TP: temporal-parietal cortex
ST1: fetal (13 - 26 postconception weeks), ST2: early infancy to late childhood (4 months to 11 years), and ST3: adolescence to adulthood (13 - 23 years)
The bar shown representes average value of the expressions.

Top Co-expressed Genes in Brain-Frontal Cortex (BA9) (GTEx v7)

Top 10 positively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
KIAA1549L0.96
RIMBP20.959
MYT1L0.956
THRB0.954
ITPR10.95
SLC12A50.949
INPP4A0.949
DLGAP20.948
ADD20.945
AJAP10.945

Top 10 negatively co-expressed genes

Gene Symbol Pearson Correlation Coefficient
MYL3-0.583
SNHG18-0.581
CSAG1-0.573
COPZ2-0.565
TFPI2-0.561
GNG11-0.56
RAB13-0.559
HEY2-0.551
RAI14-0.543
CMTM3-0.541

Drugs/Compounds

    There is no DrugBank record for this gene !

ID Drug Name Action PubMed
C0297902,2',3',4,4',5-hexachlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of SHANK2 mRNA"25510870
C1111182',3,3',4',5-pentachloro-4-hydroxybiphenyl"2',3,3',4',5-pentachloro-4-hydroxybiphenyl results in decreased expression of SHANK2 mRNA"19114083
C0817662,4,4'-trichlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of SHANK2 mRNA"25510870
C0140242,4,5,2',4',5'-hexachlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of SHANK2 mRNA"25510870
C0098282,4,5,2',5'-pentachlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of SHANK2 mRNA"25510870
C0094072,5,2',5'-tetrachlorobiphenyl"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of SHANK2 mRNA"25510870
C0230353,4,5,3',4'-pentachlorobiphenyl"3,4,5,3',4'-pentachlorobiphenyl results in increased expression of SHANK2 mRNA"28973690
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with methylmercuric chloride co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SHANK2 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SHANK2 mRNA"27188386
C4591794-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SHANK2 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with methylmercuric chloride co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SHANK2 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SHANK2 mRNA"27188386
C516138(6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SHANK2 mRNA"27188386
C496492abrineabrine results in increased expression of SHANK2 mRNA22595364
D000082AcetaminophenAcetaminophen results in decreased expression of SHANK2 mRNA29067470
D000082Acetaminophen[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of SHANK2 mRNA25607892
D016604Aflatoxin B1Aflatoxin B1 affects the expression of SHANK2 protein20106945
D016604Aflatoxin B1Aflatoxin B1 results in decreased expression of SHANK2 mRNA21641981|2210060
D016604Aflatoxin B1Aflatoxin B1 results in decreased methylation of SHANK2 gene27153756
D000535Aluminum[APP protein modified form binds to Aluminum] which results in increased expression of SHANK2 mRNA21298039
D000643Ammonium ChlorideAmmonium Chloride affects the expression of SHANK2 mRNA16483693
D000726Androgen Antagonists[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of SHANK2 mRNA25607892
D001151ArsenicArsenic affects the methylation of SHANK2 gene25304211
C006632arsenic trioxidearsenic trioxide results in decreased expression of SHANK2 mRNA24831965
D001280AtrazineAtrazine results in decreased expression of SHANK2 mRNA25929836
D001564Benzo(a)pyreneBenzo(a)pyrene affects the expression of SHANK2 mRNA21714911|2569089
D001564Benzo(a)pyreneBenzo(a)pyrene results in decreased expression of SHANK2 mRNA20106945|2163298
D0151237,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide"7,8-Dihydro-7,8-dihydroxybenzo(a)pyrene 9,10-oxide results in decreased expression of SHANK2 mRNA"26238291
C006780bisphenol Abisphenol A results in decreased methylation of SHANK2 promoter27312807
C006780bisphenol Abisphenol A results in increased methylation of SHANK2 promoter27312807
C006780bisphenol A[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of SHANK2 mRNA25607892
C006780bisphenol A[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of SHANK2 mRNA25607892
C006780bisphenol Abisphenol A results in decreased expression of SHANK2 mRNA25181051
C006780bisphenol Abisphenol A results in increased methylation of SHANK2 gene28505145
C038091butylparaben[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of SHANK2 mRNA25607892
C038091butylparaben[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of SHANK2 mRNA25607892
D002220CarbamazepineCarbamazepine affects the expression of SHANK2 mRNA25979313
C018021cobaltous chloridecobaltous chloride results in decreased expression of SHANK2 mRNA24386269
D003042CocaineCocaine results in decreased expression of SHANK2 mRNA18000554
D003300Copper[NSC 689534 binds to Copper] which results in increased expression of SHANK2 mRNA20971185
D003300CopperCopper results in decreased expression of SHANK2 protein25007851
D003300CopperCopper inhibits the reaction [Potassium results in increased expression of SHANK2 protein]25007851
D003300CopperCopper inhibits the reaction [zinc chloride results in increased expression of SHANK2 protein]25007851
D019327Copper SulfateCopper Sulfate affects the expression of SHANK2 mRNA19549813
C029892cupric chloride[COMMD1 protein co-treated with zinc chloride co-treated with cupric chloride] results in increased expression of SHANK2 protein25007851
D016572CyclosporineCyclosporine results in decreased expression of SHANK2 mRNA20106945|2556210
D003993Dibutyl Phthalate[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of SHANK2 mRNA25607892
D003999Dichloroacetic AcidDichloroacetic Acid results in decreased expression of SHANK2 mRNA28962523
D002945Cisplatin[Cisplatin co-treated with jinfukang] results in decreased expression of SHANK2 mRNA27392435
D002945CisplatinCisplatin results in decreased expression of SHANK2 mRNA27392435
D002945CisplatinCisplatin results in decreased expression of SHANK2 mRNA22023808
D003633Dichlorodiphenyl Dichloroethylene[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of SHANK2 mRNA25607892
C000944dicrotophosdicrotophos results in increased expression of SHANK2 mRNA28302478
D004041Dietary FatsDietary Fats results in increased expression of SHANK2 mRNA25016146
D004051Diethylhexyl Phthalate[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of SHANK2 mRNA25607892
C038939enzacamene[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of SHANK2 mRNA25607892
C038939enzacamene[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of SHANK2 mRNA25607892
C109476epoxiconazole[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of SHANK2 mRNA25607892
C082360fipronilfipronil results in increased expression of SHANK2 mRNA23962444
C071834glycidamideglycidamide results in decreased expression of SHANK2 mRNA17822822
C412815GW 4064GW 4064 results in increased expression of SHANK2 mRNA26655953
D006830Hydralazine[Hydralazine co-treated with Valproic Acid] results in increased expression of SHANK2 mRNA17183730
D006861Hydrogen PeroxideHydrogen Peroxide affects the expression of SHANK2 mRNA20044591
C475919hydroxytamoxifenhydroxytamoxifen results in increased expression of SHANK2 mRNA16849584
C544151jinfukang[Cisplatin co-treated with jinfukang] results in decreased expression of SHANK2 mRNA27392435
D007854LeadLead affects the expression of SHANK2 mRNA28903495
D008044Linuron[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of SHANK2 mRNA25607892
D008558MelphalanMelphalan results in decreased expression of SHANK2 mRNA22363485
C004925methylmercuric chloridemethylmercuric chloride results in increased expression of SHANK2 mRNA23179753|2627250
C004925methylmercuric chloride"[NOG protein co-treated with methylmercuric chloride co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SHANK2 mRNA"27188386
D008741Methyl MethanesulfonateMethyl Methanesulfonate results in decreased expression of SHANK2 mRNA23649840
D037742Nanotubes, Carbon"Nanotubes, Carbon analog results in decreased expression of SHANK2 mRNA"25620056
D009532NickelNickel results in decreased expression of SHANK2 mRNA24768652|2558310
C029938nickel sulfatenickel sulfate results in decreased expression of SHANK2 mRNA22714537
D005996NitroglycerinNitroglycerin results in increased expression of SHANK2 mRNA12102619
C558013NSC 689534[NSC 689534 binds to Copper] which results in increased expression of SHANK2 mRNA20971185
C118580octylmethoxycinnamate[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben co-treated with Androgen Antagonists co-treated with Acetaminophen] results in decreased expression of SHANK2 mRNA25607892
C118580octylmethoxycinnamate[bisphenol A co-treated with enzacamene co-treated with octylmethoxycinnamate co-treated with butylparaben] results in decreased expression of SHANK2 mRNA25607892
C410127PCB 180"[2,4,4'-trichlorobiphenyl co-treated with 2,5,2',5'-tetrachlorobiphenyl co-treated with 2,4,5,2',5'-pentachlorobiphenyl co-treated with 2,2',3',4,4',5-hexachlorobiphenyl co-treated with 2,4,5,2',4',5'-hexachlorobiphenyl co-treated with PCB 180] results in decreased expression of SHANK2 mRNA"25510870
C101814perfluoro-n-undecanoic acidperfluoro-n-undecanoic acid results in increased expression of SHANK2 mRNA23602845
D010936Plant ExtractsPlant Extracts results in decreased expression of SHANK2 mRNA23557933
D059808PolyphenolsPolyphenols results in decreased expression of SHANK2 mRNA16293270
D011188PotassiumCopper inhibits the reaction [Potassium results in increased expression of SHANK2 protein]25007851
D011188PotassiumPotassium results in increased expression of SHANK2 protein25007851
C045362prochloraz[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of SHANK2 mRNA25607892
C035988procymidone[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of SHANK2 mRNA25607892
C005556propionaldehydepropionaldehyde results in increased expression of SHANK2 mRNA26079696
D012643SeleniumSelenium results in decreased expression of SHANK2 mRNA19244175
D012822Silicon DioxideSilicon Dioxide analog results in decreased expression of SHANK2 mRNA25895662
D012822Silicon DioxideSilicon Dioxide results in increased expression of SHANK2 mRNA25351596
D012834SilverSilver results in decreased expression of SHANK2 mRNA26551752
C016104sodium bichromatesodium bichromate affects the expression of SHANK2 mRNA22110744
C105686SU 5402SU 5402 affects the expression of SHANK2 mRNA15298682
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin results in increased expression of SHANK2 mRNA20106945
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin affects the expression of SHANK2 mRNA26377647
D013749TetrachlorodibenzodioxinTetrachlorodibenzodioxin results in decreased expression of SHANK2 mRNA26290441
D013755Tetradecanoylphorbol Acetate[Zinc co-treated with Tetradecanoylphorbol Acetate] affects the expression of SHANK2 mRNA16979875
D014212TretinoinTretinoin results in decreased expression of SHANK2 mRNA21934132|2383079
D014212TretinoinTretinoin results in increased expression of SHANK2 mRNA23724009
C012589trichostatin A"[NOG protein co-treated with trichostatin A co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SHANK2 mRNA"27188386
C012589trichostatin Atrichostatin A results in increased expression of SHANK2 mRNA24935251|2627250
D014520UrethaneUrethane affects the expression of SHANK2 mRNA28818685
D014635Valproic Acid[Hydralazine co-treated with Valproic Acid] results in increased expression of SHANK2 mRNA17183730
D014635Valproic Acid"[NOG protein co-treated with Valproic Acid co-treated with (6-(4-(2-piperidin-1-ylethoxy)phenyl))-3-pyridin-4-ylpyrazolo(1,5-a)pyrimidine co-treated with 4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide] results in increased expression of SHANK2 mRNA"27188386
D014635Valproic AcidValproic Acid affects the expression of SHANK2 mRNA25979313
D014635Valproic AcidValproic Acid results in increased expression of SHANK2 mRNA23179753|2438349
D014635Valproic AcidValproic Acid results in increased methylation of SHANK2 gene29154799
D000069470Venlafaxine HydrochlorideVenlafaxine Hydrochloride results in increased expression of SHANK2 mRNA25423262
C025643vinclozolin[Dibutyl Phthalate co-treated with Diethylhexyl Phthalate co-treated with vinclozolin co-treated with prochloraz co-treated with procymidone co-treated with Linuron co-treated with epoxiconazole co-treated with Dichlorodiphenyl Dichloroethylene] results in decreased expression of SHANK2 mRNA25607892
D014810Vitamin EVitamin E results in decreased expression of SHANK2 mRNA19244175
D024483Vitamin K 3Vitamin K 3 affects the expression of SHANK2 mRNA20044591
C111237vorinostatvorinostat results in decreased expression of SHANK2 mRNA27188386
D015032Zinc[Zinc co-treated with Tetradecanoylphorbol Acetate] affects the expression of SHANK2 mRNA16979875
C016837zinc chloride[COMMD1 protein co-treated with zinc chloride co-treated with cupric chloride] results in increased expression of SHANK2 protein25007851
C016837zinc chlorideCopper inhibits the reaction [zinc chloride results in increased expression of SHANK2 protein]25007851
C016837zinc chloridezinc chloride results in increased expression of SHANK2 protein25007851

GO/Pathway

GO ID GO Term Qualifier Evidence PubMed
GO:0005515protein binding-IPI11583995  17474147  
GO:0017124SH3 domain binding-IEA-  
GO:0030159receptor signaling complex scaffold activity-IBA21873635  
GO:0030160GKAP/Homer scaffold activity-IBA21873635  
GO:0030160GKAP/Homer scaffold activity-NAS10506216  
GO:0035255ionotropic glutamate receptor binding-IBA21873635  
GO:0035255ionotropic glutamate receptor binding-ISS-  
GO ID GO Term Qualifier Evidence PubMed
GO:0007416synapse assembly-IBA21873635  
GO:0007416synapse assembly-ISS22699620  
GO:0007612learning-IMP20473310  
GO:0030534adult behavior-IMP20473310  
GO:0035176social behavior-IMP20473310  
GO:0048854brain morphogenesis-IBA21873635  
GO:0051124synaptic growth at neuromuscular junction-IBA21873635  
GO:0051705multi-organism behavior-IBA21873635  
GO:0051968positive regulation of synaptic transmission, glutamatergic-IBA21873635  
GO:0060291long-term synaptic potentiation-IBA21873635  
GO:0060291long-term synaptic potentiation-ISS22699620  
GO:0060292long term synaptic depression-ISS22699620  
GO:0060997dendritic spine morphogenesis-IBA21873635  
GO:0060999positive regulation of dendritic spine development-IBA21873635  
GO:0071625vocalization behavior-IMP20473310  
GO:0097107postsynaptic density assembly-IBA21873635  
GO:2000311regulation of AMPA receptor activity-IBA21873635  
GO:2000463positive regulation of excitatory postsynaptic potential-IBA21873635  
GO ID GO Term Qualifier Evidence PubMed
GO:0001750photoreceptor outer segment-ISS-  
GO:0001917photoreceptor inner segment-ISS-  
GO:0005575cellular_component-ND-  
GO:0005829cytosol-TAS-  
GO:0005883neurofilamentcolocalizes_withISS-  
GO:0005886plasma membrane-IBA21873635  
GO:0005886plasma membraneCOLOCALIZES_WITHIBA21873635  
GO:0005886plasma membrane-ISS-  
GO:0008328ionotropic glutamate receptor complexCOLOCALIZES_WITHIBA21873635  
GO:0008328ionotropic glutamate receptor complexcolocalizes_withISS-  
GO:0014069postsynaptic density-IBA21873635  
GO:0014069postsynaptic density-ISS-  
GO:0016324apical plasma membrane-ISS-  
GO:0030054cell junction-IEA-  
GO:0030425dendrite-IBA21873635  
GO:0030426growth cone-ISS-  
GO:0031526brush border membrane-ISS-  
GO:0043005neuron projection-IBA21873635  
GO:0043005neuron projection-ISS-  
GO:0043025neuronal cell body-ISS-  
GO:0043197dendritic spine-IBA21873635  
GO:0043197dendritic spine-ISS-  
GO:0044309neuron spine-IBA21873635  
GO:0045211postsynaptic membraneCOLOCALIZES_WITHIBA21873635  
GO:0045211postsynaptic membranecolocalizes_withISS-  
GO:0060170ciliary membrane-ISS-  
KEGG ID KEGG Term
Reactome ID Reactome Term Evidence
R-HSA-112316Neuronal SystemIEA
R-HSA-112316Neuronal SystemTAS
R-HSA-6794361Neurexins and neuroliginsIEA
R-HSA-6794361Neurexins and neuroliginsTAS
R-HSA-6794362Protein-protein interactions at synapsesIEA
R-HSA-6794362Protein-protein interactions at synapsesTAS

Interactions (STRING v10.5, Interaction Score >= 0.400)

Publications (Co-occurrence of gene symbol strings and ANCO-Dependence terms)

PMID Title (Year) Author Journal
28852427Seven-CpG-based prognostic signature coupled with gene expression predicts survival of oral squamous cell carcinoma. (2017)Shen SClin Epigenetics
29618728Association between DNA methylation in cord blood and maternal smoking: The Hokkaido Study on Environment and Children's Health. (2018 Apr 4)Miyake KSci Rep